NPM1 and acute myeloid leukemia: In contrast to European LeukemiaNet (ELN) 2017 AML risk stratification criteria that classified FLT3-ITD mutation with AR of > 0.5 in an absence of NPM1 mutation as an adverse risk, the updated ELN 2022 guidelines re-classify all FLT3-ITD mutated AML (without adverse cytogenetics) as intermediate risks, irrespective of AR or NPM1 mutation status.